Headlines

Sanofi (SAN FP) and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

Newsquawk Staff ·

Sanofi (SAN FP) and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease.

What it means

Sanofi's phase 2b trial results for duvakitug showing durable efficacy in ulcerative colitis and Crohn's disease may boost investor confidence in its product pipeline and market position. Clinical milestones like this can drive stock momentum and have positive read-through for the broader pharmaceuticals sector, particularly if they lead to regulatory submissions or partnerships.

Related headlines